XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
27.76
+0.62 (2.28%)
Jul 14, 2025, 4:00 PM - Market closed
XOMA Royalty Revenue
XOMA Royalty had revenue of $15.91M in the quarter ending March 31, 2025, with 967.92% growth. This brings the company's revenue in the last twelve months to $42.91M, up 638.41% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$42.91M
Revenue Growth
+638.41%
P/S Ratio
7.63
Revenue / Employee
$3,300,692
Employees
13
Market Cap
332.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
XOMA News
- 13 hours ago - ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction - PRNewsWire
- 8 days ago - Collect Up To 11.5% From The Healthcare Sector - Seeking Alpha
- 17 days ago - Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right - GlobeNewsWire
- 26 days ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 6 weeks ago - XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - GlobeNewsWire
- 2 months ago - XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference - GlobeNewsWire
- 3 months ago - XOMA Royalty Completes Sale of Kinnate Pipeline Assets - GlobeNewsWire
- 3 months ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire